argenx SE American Depositary Shares ARGX
i
Market datapartial · fetched 2026-11-12T04:15:19.304Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-11T23:57:41.753548432Z
FundamentalsAlpha Vantage · unavailable
argenx SE American Depositary Shares options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 1032.67 | 38.8% | 6.3% | 929.39 | 40.5% | 5.7% |
| 25Δ | 1020.74 | 38.1% | 5.3% | 940.08 | 39.7% | 4.8% |
| 30Δ | 1012.06 | 38.3% | 4.7% | 949.46 | 38.8% | 4.1% |
| 35Δ | 1003.59 | 38.5% | 4.1% | 957.76 | 38.3% | 3.5% |
| 40Δ | 995.56 | 38.7% | 3.5% | 965.45 | 38.2% | 3.0% |
| 45Δ | 987.87 | 38.6% | 3.0% | 972.89 | 38.2% | 2.6% |
| 50Δ | 980.24 | 37.9% | 2.6% | 980.25 | 38.1% | 2.2% |
| 55Δ | 972.72 | 39.1% | 2.3% | 987.22 | 36.9% | 1.8% |
| 60Δ | 964.96 | 39.8% | 1.9% | 994.30 | 36.1% | 1.5% |
| 65Δ | 957.08 | 39.8% | 1.6% | 1001.68 | 35.8% | 1.2% |
| 70Δ | 949.08 | 39.4% | 1.3% | 1010.00 | 35.9% | 1.0% |
| 75Δ | 939.59 | 40.2% | 1.1% | 1018.32 | 36.0% | 0.7% |
| 80Δ | 928.65 | 41.1% | 0.8% | 1029.03 | 36.3% | 0.5% |
20Δ
- Pseudo strike
- 1032.67
- IV
- 38.8%
- B/E move
- 6.3%
- Pseudo strike
- 929.39
- IV
- 40.5%
- B/E move
- 5.7%
25Δ
- Pseudo strike
- 1020.74
- IV
- 38.1%
- B/E move
- 5.3%
- Pseudo strike
- 940.08
- IV
- 39.7%
- B/E move
- 4.8%
30Δ
- Pseudo strike
- 1012.06
- IV
- 38.3%
- B/E move
- 4.7%
- Pseudo strike
- 949.46
- IV
- 38.8%
- B/E move
- 4.1%
35Δ
- Pseudo strike
- 1003.59
- IV
- 38.5%
- B/E move
- 4.1%
- Pseudo strike
- 957.76
- IV
- 38.3%
- B/E move
- 3.5%
40Δ
- Pseudo strike
- 995.56
- IV
- 38.7%
- B/E move
- 3.5%
- Pseudo strike
- 965.45
- IV
- 38.2%
- B/E move
- 3.0%
45Δ
- Pseudo strike
- 987.87
- IV
- 38.6%
- B/E move
- 3.0%
- Pseudo strike
- 972.89
- IV
- 38.2%
- B/E move
- 2.6%
50Δ
- Pseudo strike
- 980.24
- IV
- 37.9%
- B/E move
- 2.6%
- Pseudo strike
- 980.25
- IV
- 38.1%
- B/E move
- 2.2%
55Δ
- Pseudo strike
- 972.72
- IV
- 39.1%
- B/E move
- 2.3%
- Pseudo strike
- 987.22
- IV
- 36.9%
- B/E move
- 1.8%
60Δ
- Pseudo strike
- 964.96
- IV
- 39.8%
- B/E move
- 1.9%
- Pseudo strike
- 994.30
- IV
- 36.1%
- B/E move
- 1.5%
65Δ
- Pseudo strike
- 957.08
- IV
- 39.8%
- B/E move
- 1.6%
- Pseudo strike
- 1001.68
- IV
- 35.8%
- B/E move
- 1.2%
70Δ
- Pseudo strike
- 949.08
- IV
- 39.4%
- B/E move
- 1.3%
- Pseudo strike
- 1010.00
- IV
- 35.9%
- B/E move
- 1.0%
75Δ
- Pseudo strike
- 939.59
- IV
- 40.2%
- B/E move
- 1.1%
- Pseudo strike
- 1018.32
- IV
- 36.0%
- B/E move
- 0.7%
80Δ
- Pseudo strike
- 928.65
- IV
- 41.1%
- B/E move
- 0.8%
- Pseudo strike
- 1029.03
- IV
- 36.3%
- B/E move
- 0.5%
Options history
Table
| Date | IV (%) |
|---|---|
| 42.82% | |
| 42.43% | |
| 35.86% | |
| 34.52% | |
| 35.67% | |
| 34.52% | |
| 34.45% | |
| 35.23% | |
| 34.46% | |
| 35.55% | |
| 35.17% | |
| 34.64% | |
| 34.90% | |
| 34.94% | |
| 34.66% | |
| 34.13% | |
| 34.38% | |
| 35.88% | |
| 35.50% | |
| 35.47% | |
| 34.71% | |
| 36.34% | |
| 36.41% | |
| 37.52% | |
| 37.32% | |
| 36.90% | |
| 37.26% | |
| 37.53% | |
| 37.56% | |
| 37.28% | |
| 37.40% | |
| 37.89% | |
| 37.56% | |
| 37.53% | |
| 38.24% | |
| 38.29% | |
| 38.22% | |
| 38.45% | |
| 38.55% | |
| 38.00% | |
| 36.92% | |
| 38.57% | |
| 38.87% | |
| 40.64% | |
| 41.66% | |
| 42.38% | |
| 42.74% | |
| 42.73% | |
| 42.70% | |
| 37.58% | |
| 38.12% | |
| 38.28% | |
| 37.95% | |
| 37.61% | |
| 37.77% | |
| 39.33% |
Biotechnology
ARMP
Armata Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of specific bacteriophage therapies for the treatment of antibiotic-resistant…
More →ARQT
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. The company is headquartered in…
More →ARTV
Artiva Biotherapeutics, Inc. is a cutting-edge biotechnology firm dedicated to revolutionizing cancer therapy through its proprietary natural killer (NK) cell platform. With a…
More →ARVN
Arvinas, Inc., a clinical-stage biopharmaceutical company, is dedicated to the discovery, development, and commercialization of therapies to break down disease-causing proteins.…
More →ARWR
Arrowhead Pharmaceuticals, Inc. develops drugs for the treatment of intractable diseases in the United States. The company is headquartered in Pasadena, California.
More →ASMB
Assembly Biosciences, Inc. is a clinical-stage biotechnology company in the United States. The company is headquartered in South San Francisco, California.
More →